Dianthus Therapeutics’ claseprubart has met its primary and secondary endpoints during a Phase II trial in generalised myasthenia gravis (gMG). During the MaGic study (NCT06282159), the active ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback